Vanda Pharmaceuticals Inc. (VNDA): who owns it and who trades it
As of Nov 16, 2026, VNDA insiders reported 6 open-market sales worth $2.8M and 3 purchases worth $38.1K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mihael Hristos Polymeropoulos (CEO), with $1.3M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vanda Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VNDA
170 funds and institutions reported VNDA shares worth $308M at the end of Q2 2026, about 84% of the company. The largest holder is BlackRock, Inc. with 12.7%.
Funds and institutions (13F) 84%Everyone else 16%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 7.65M | 12.73% | $46.8M | +5% |
| State Street Corp | 3.52M | 5.85% | $21.5M | +17% |
| AQR Capital Management LLC | 3.50M | 5.82% | $21.4M | +118% |
| Renaissance Technologies LLC | 3.44M | 5.72% | $21.1M | -8% |
| Vanguard Capital Management LLC | 2.52M | 4.20% | $15.4M | +2% |
| AIGH Capital Management LLC | 2.04M | 3.40% | $12.5M | -26% |
| Acadian Asset Management LLC | 1.92M | 3.19% | $11.7M | +7% |
| Dimensional Fund Advisors LP | 1.73M | 2.87% | $10.6M | -2% |
| Millennium Management LLC | 1.60M | 2.67% | $9.8M | -15% |
| Geode Capital Management, LLC | 1.48M | 2.47% | $9.1M | +3% |
| Two Sigma Investments, LP | 1.35M | 2.24% | $8.3M | -4% |
| Marshall Wace, LLP | 1.23M | 2.04% | $7.5M | +106% |
| Jacobs Levy Equity Management, Inc | 1.21M | 2.02% | $7.4M | +4% |
| Krensavage Asset Management, LLC | 1.18M | 1.96% | $7.2M | No change |
| Vanguard Portfolio Management LLC | 1.13M | 1.88% | $6.9M | +11% |
| Goldman Sachs Group Inc | 1.04M | 1.72% | $6.3M | +24% |
| Citadel Advisors LLC | 758,302 | 1.26% | $4.6M | +20% |
| Qube Research & Technologies Ltd | 729,212 | 1.21% | $4.5M | – |
| Federated Hermes, Inc. | 714,278 | 1.19% | $4.4M | +24% |
| Charles Schwab Investment Management Inc | 646,256 | 1.07% | $4M | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VNDA insiders reported $38.1K of open-market purchases and $2.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Charles Cliff Duncan | Director | Purchase | 5,803 | $3.80 | $22.1K | Form 4 |
| Nov 4, 2026 | Charles Cliff Duncan | Director | Purchase | 3,447 | $3.82 | $13.2K | Form 4 |
| Nov 3, 2026 | Charles Cliff Duncan | Director | Purchase | 750 | $3.80 | $2.8K | Form 4 |
| Mar 2, 2026 | Timothy Williams | Vice president | Sale | 42,434 | $8.27 | $351K | Form 4 |
| Mar 2, 2026 | Kevin Patrick Moran | CFO | Sale | 42,442 | $8.27 | $351K | Form 4 |
| Mar 2, 2026 | Joakim Wijkstrom | Vice president | Sale | 30,800 | $8.27 | $255K | Form 4 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos | CEO | Sale | 156,235 | $8.17 | $1.3M | Form 4 |
| Mar 2, 2026 | Gunther Birznieks | Vice president | Sale | 42,431 | $8.27 | $351K | Form 4 |
| Feb 23, 2026 | Tage Honore | Director | Sale | 30,000 | $8.03 | $241K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mihael Hristos Polymeropoulos | President and CEO, Director | – | $1.3M | Mar 2, 2026 |
| Kevin Patrick Moran | SVP, CFO & Treasurer | – | $351K | Mar 2, 2026 |
| Timothy Williams | SVP & General Counsel | – | $351K | Mar 2, 2026 |
| Gunther Birznieks | SVP, Business Development | – | $351K | Mar 2, 2026 |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | – | $255K | Mar 2, 2026 |
| Tage Honore | Director | – | $241K | Feb 23, 2026 |
| Charles Cliff Duncan | Director | $38.1K | – | Nov 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VNDA short interest
High short interest. 12.6% of VNDA shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.62M VNDA shares were sold short, 12.6% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 5.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.62M | 12.61% | -8% | 1.28M | 5.9 |
| Oct 15, 2026 | 8.31M | 13.74% | +6% | 1.00M | 8.3 |
| Sep 30, 2026 | 7.83M | 12.95% | -8% | 1.21M | 6.5 |
| Sep 15, 2026 | 8.50M | 14.05% | +11% | 703,578 | 12.1 |
| Aug 31, 2026 | 7.69M | 12.71% | +0% | 778,741 | 9.9 |
| Aug 14, 2026 | 7.67M | 12.68% | +3% | 1.25M | 6.2 |
| Jul 31, 2026 | 7.42M | 12.28% | +3% | 824,875 | 9.0 |
| Jul 15, 2026 | 7.19M | 11.95% | -2% | 816,704 | 8.8 |
| Jun 30, 2026 | 7.34M | 12.21% | +5% | 932,697 | 7.9 |
| Jun 15, 2026 | 6.99M | 11.62% | +3% | 898,460 | 7.8 |
| May 29, 2026 | 6.81M | 11.33% | +7% | 1.00M | 6.8 |
| May 15, 2026 | 6.37M | 10.59% | +3% | 1.30M | 4.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Vanda Pharmaceuticals company events
Vanda Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 28, 2026.
- Oct 28, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 22, 2026LeadershipThe Board of Directors of Vanda Pharmaceuticals Inc. expanded the size of the Board from six to seven members, effective immediately and appointed Charles C. Duncan, Ph.D., as a director of the Company to fill the vacancy created by the expansion. Filing
- Apr 2, 2026LeadershipTimothy Williams notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026, in order to pursue other endeavors. Filing
- Mar 10, 2026AnnouncementShared information with investors. Filing
- Feb 23, 2026AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved Bysanti TM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults. Filing
- Feb 19, 2026LeadershipThe Compensation Committee of the Board of Directors of Vanda Pharmaceuticals Inc. awarded 2025 annual bonuses and approved 2026 annual base salaries and 2026 bonus target amounts for the Company’s named executive officers. Filing
- Feb 11, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementAs previously disclosed, on October 1, 2025, Vanda Pharmaceuticals Inc. announced that it had reached a collaborative framework with the U.S. Food and Drug Administration pursuant to which, among other things, the FDA had agreed to conduct an expedited re-review of Vanda’s supplemental New Drug… Filing
- Dec 31, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUS TM (tradipitant) for the prevention of vomiting induced by motion. Filing
- Dec 4, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has lifted the partial clinical hold on Vanda’s drug, tradipitant, for the treatment of motion sickness. Filing
- Nov 28, 2025AnnouncementVanda Pharmaceuticals Inc. issued a press release providing a regulatory update on Vanda’s drug, tradipitant, for the treatment of motion sickness. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Vanda Pharmaceuticals financials
Famous investors that hold VNDA
6 of the 50 well-known investors we track reported holding VNDA in their latest 13F filing. The largest position is Israel Englander's, worth $20.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.26M | $20.9M | 0.0% | +166% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 3.31M | $16.2M | 0.0% | -4% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 102,409 | $503K | 0.0% | -67% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 74,039 | $364K | 0.0% | -90% |
| Jeremy Grantham · GMO | Q3 2026 | 21,737 | $107K | 0.0% | -23% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 14,402 | $70.7K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named VNDA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 3.5% |
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 3.5% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.9% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.9% |
| Oct 9, 2026 | Millennium Management LLC | 13G/A | 7.0% |
| Oct 9, 2026 | Millennium Management LLC | 13G/A | 7.0% |
Questions about Vanda Pharmaceuticals Inc. (VNDA) stock
Who owns the most VNDA stock?
The largest reported owner of Vanda Pharmaceuticals Inc. (VNDA) is BlackRock, Inc., with 12.7% of the company. In total, 170 funds and institutions reported holding VNDA at the end of Q2 2026, together about 84% of the shares. See the largest owners.
Are VNDA insiders buying or selling?
In the last 12 months, VNDA insiders reported 3 open-market purchases worth $38.1K and 6 sales worth $2.8M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in VNDA?
As of Oct 30, 2026, 7.62M VNDA shares were sold short, 12.6% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 5.9 trading days (days to cover). See the history.
Which famous investors hold VNDA?
6 of the 50 well-known investors we track reported VNDA in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $20.9M. See all holders.
Executive pay
Vanda Pharmaceuticals's chief executive was paid a total of $3.9M for the year ended Dec 31, 2025, down 1% from $3.9M the year before. In the last 12 months, Vanda Pharmaceuticals's executives and directors bought $38.1K of stock on the open market and sold $2.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.